Skip to main
ENGN
ENGN logo

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is positioned for significant growth within the market, particularly due to its dually derived chitosan (DDX) gene delivery platform, which has received RMAT designation, enhancing its potential to capture substantial market share in community practice settings. The company’s ongoing LEGEND study indicates additional commercial opportunities, with potential market expansion into earlier disease stages and active surveillance through various cohorts that could broaden its addressable market. Additionally, while research and development expenses rose to $22.6 million in the third quarter of 2025, a considerable increase from $11.5 million the previous year, this investment underscores the company's commitment to advancing its clinical programs and ultimately increasing its market presence.

Bears say

The financial outlook for enGene Holdings Inc. appears negative primarily due to the potential for regulatory approval delays, which could adversely affect the company's share price and investor confidence. Additionally, the operational challenges associated with TAR-200, including a significant procedural burden and a notable rate of serious adverse events (SAE), may hinder its market acceptance and uptake. These factors, combined with the competitive landscape, suggest that the company's commercial prospects could be compromised, further impacting its financial performance.

ENGN has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 6 analysts, ENGN has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.